AbCellera Biologics Inc. (ABCL) Financials
ABCL Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 1.5 billion | 335.8 million |
| 2023-09-30 | 1.5 billion | 329.4 million |
| 2023-06-30 | 1.5 billion | 342.3 million |
| 2023-03-31 | 1.5 billion | 289.4 million |
ABCL Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | -34.0 million | 16.4 million |
| 2023-09-30 | -21.0 million | 15.9 million |
| 2023-06-30 | -7.3 million | 16.4 million |
| 2023-03-31 | -59.0 million | 15.5 million |
ABCL Net Income
Graph available only for supporters. Become a supporter to see it.
| Date | Net Income |
|---|---|
| 2023-12-31 | -47.2 million |
| 2023-09-30 | -28.6 million |
| 2023-06-30 | -30.5 million |
| 2023-03-31 | -40.1 million |
ABCL Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 760.6 million | - | 77.4 million |
| 2023-09-30 | 785.8 million | - | 80.8 million |
| 2023-06-30 | 795.7 million | - | 84.0 million |
| 2023-03-31 | 796.5 million | - | 83.1 million |
ABCL Shares Outstanding
ABCL Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 14.4 million | 48.6 million | 16.0 million | 3.1 million |
| 2023-09-30 | 20.9 million | 37.9 million | 14.4 million | 3.5 million |
| 2023-06-30 | 27.2 million | 36.5 million | 15.5 million | 3.8 million |
| 2023-03-31 | 15.0 million | 52.6 million | 15.1 million | 3.8 million |
ABCL Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 9.2 million | 9.1 million |
| 2023-09-30 | 6.6 million | 7.4 million |
| 2023-06-30 | 10.1 million | 7.3 million |
| 2023-03-31 | 12.2 million | 52.6 million |
ABCL
Price: $4.03
52 week price:
Earnings Per Share: -0.51 USD
P/E Ratio: -11.16
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.3 million
Market Capitalization: 1.3 billion